RRML - Fluorescence In Situ Hybridization on peripheral blood is a sensitive and reliable method for evaluation of minimal residual disease in CML
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2020): 1.027

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- October 2021 -
 
Atellica CH 930 chemistry anal... 13
Cell Cycle Regulatory CCND1 G8... 11
Circulating amino acids as fin... 8
Romanian Review of Laboratory ... 7
COVID-19 associated coagulopat... 7
Insights into Innate Immune Re... 6
VEGF-C and podoplanin, as biom... 6
Evaluation of the impact of Co... 6
Mutations in the KRAS gene as ... 6
Correction factor between two ... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 20(2)/2012
XML
TXT

Fluorescence In Situ Hybridization on peripheral blood is a sensitive and reliable method for evaluation of minimal residual disease in CML

Cerasela Jardan, Dumitru Jardan, Daniel Coriu, Emilia Severin


Abstract:

This study was aimed to investigate the value of detecting BCR/ABL fusion gene by fluorescence in situ hybridization (FISH) on peripheral blood specimens from patients with chronic myeloid leukemia (CML). Mate-rials and Methods: We analyzed 126 samples (83 bone marrow and 43 peripheral blood samples) from patients with CML referred to Fundeni Clinical Institute between 2010 and 2011. Samples were analyzed using interphase FISH on peripheral-blood specimens and the results were compared with those of conventional cytogenetics and interphase FISH on bone marrow. Results: in comparison to conventional cytogenetics and bone marrow FISH, interphasic FISH on peripheral blood did not generated any discrepancies regarding the level of minimal residual disease. Conclusion: In this study we evaluated FISH technique as an alternative and rapid method for monitoring minimal residual disease in CML patients treated with tyrosine kinase inhibitors. FISH on peripheral blood is a molecular cytogenetic technique that allows minimal residual disease monitoring on interphase nuclei. This technique has the advantage of generating results in a short time (even in 24h) and is less invasive than bone marrow biopsy.

Keywords: peripheral blood-FISH technique,BCR/ABL gene fusion,minimal residual disease

 
  PDF Download full text PDF
(207 KB)
     
 
How to cite
Jardan C, Jardan D, Coriu D, Severin E. Fluorescence In Situ Hybridization on peripheral blood is a sensitive and reliable method for evaluation of minimal residual disease in CML. Rev Romana Med Lab. 2012;20(2):151-6